Green Cross Biotherapeutics - Ownership and Business Overview

Life ScienceCompany

Green Cross Biotherapeutics Ownership

Who owns Green Cross Biotherapeutics?

Green Cross Biotherapeutics is owned by Stonebridge Capital. It was acquired on January 1, 2015.

Is Green Cross Biotherapeutics PE-backed?

Yes. Green Cross Biotherapeutics is owned by private equity investor Stonebridge Capital.

Green Cross Biotherapeutics Business Overview

Where is Green Cross Biotherapeutics headquartered?

Green Cross Biotherapeutics is headquartered in Montreal, Quebec.

What sector is Green Cross Biotherapeutics in?

Green Cross Biotherapeutics is a life science company.

Life Science M&A Summary in 2015

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2015. The largest life science acquisition in 2015 was Allergan - which was acquired by Allergan for $70.5B.

Join Mergr to view all 293 acquisitions of life science companies in 2015, including 32 acquisitions by private equity firms, and 261 by strategics.

Green Cross Biotherapeutics, Inc.

7140 rue Albert-Einstein, Suite 200,
Montreal, Quebec H4S 2C1
Canada,
(514) 956-2525
www.greencrossbt.com

Green Cross Biotherapeutics, Inc. specializes in the development and manufacture of plasma derivatives, preventive vaccines, recombinant proteins and therapeutic antibodies.


 Subscribe to unlock this and 206,813
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 199K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.